CR20130560A - Compuestos de bezotiazol y su uso farmacéutico - Google Patents
Compuestos de bezotiazol y su uso farmacéuticoInfo
- Publication number
- CR20130560A CR20130560A CR20130560A CR20130560A CR20130560A CR 20130560 A CR20130560 A CR 20130560A CR 20130560 A CR20130560 A CR 20130560A CR 20130560 A CR20130560 A CR 20130560A CR 20130560 A CR20130560 A CR 20130560A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- formula
- bezotiazol
- pharmaceutical use
- aids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Abstract
La invención provee compuestos de fórmula I: R4R2R3OHOR1R3'G1G2R5I o una sal del mismo como se describe en la presente. La invención también provee composiciones farmacéuticas que comprenden un compuesto de fórmula I, procesos para preparar los compuestos de fórmula I, intermediarios útiles para preparar los compuestos de fórmula I y métodos terapéuticos que usan los compuestos de fórmula I para tratar la proliferación del virus VIH, tratar el SIDA o retrasar el inicio de los síntomas del SIDA o ARC en un mamífero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477922P | 2011-04-21 | 2011-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130560A true CR20130560A (es) | 2014-02-18 |
Family
ID=46028194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130560A CR20130560A (es) | 2011-04-21 | 2013-10-31 | Compuestos de bezotiazol y su uso farmacéutico |
Country Status (24)
Country | Link |
---|---|
US (3) | US9006229B2 (es) |
EP (2) | EP3181555B1 (es) |
JP (2) | JP5918848B2 (es) |
KR (1) | KR20140027295A (es) |
CN (2) | CN105712948A (es) |
AP (2) | AP2013007249A0 (es) |
AU (2) | AU2012245187B2 (es) |
BR (1) | BR112013027096A2 (es) |
CA (1) | CA2833377C (es) |
CL (1) | CL2013003019A1 (es) |
CO (1) | CO6801774A2 (es) |
CR (1) | CR20130560A (es) |
EA (1) | EA024952B1 (es) |
EC (1) | ECSP13013021A (es) |
ES (2) | ES2707997T3 (es) |
IL (1) | IL228925A0 (es) |
MA (1) | MA35804B1 (es) |
MX (1) | MX2013012266A (es) |
PE (1) | PE20141066A1 (es) |
PH (1) | PH12015502056A1 (es) |
PT (1) | PT2699558T (es) |
SG (1) | SG194512A1 (es) |
UA (1) | UA111841C2 (es) |
WO (1) | WO2012145728A1 (es) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
CA2802308C (en) | 2010-07-02 | 2018-08-28 | Lianhong Xu | Napht-2-ylacetic acid derivatives to treat aids |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
MD20140063A2 (ro) * | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV |
CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
AU2014205317B2 (en) | 2013-01-09 | 2016-11-24 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
TW201441197A (zh) * | 2013-01-31 | 2014-11-01 | Shionogi & Co | Hiv複製抑制劑 |
TWI706945B (zh) | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
JP6411491B2 (ja) | 2013-07-12 | 2018-10-24 | ギリアード サイエンシス インコーポレーテッド | 多環式カルバモイルピリドン化合物およびhiv感染症を処置するためのその使用 |
WO2015123230A1 (en) | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Hiv複製阻害作用を有する3環性複素環誘導体 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
NZ728072A (en) | 2014-07-11 | 2018-06-29 | Gilead Sciences Inc | Modulators of toll-like receptors for the treatment of hiv |
KR20170045308A (ko) * | 2014-08-27 | 2017-04-26 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체 |
WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体モジュレーターの固体形態 |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
NZ733135A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
KR101756050B1 (ko) | 2015-03-04 | 2017-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
AU2016244035B2 (en) | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
EP3349757A1 (en) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
WO2017059120A1 (en) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
KR102180740B1 (ko) | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
WO2018064080A1 (en) | 2016-09-28 | 2018-04-05 | Gilead Sciences, Inc. | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
US10407438B2 (en) | 2016-10-27 | 2019-09-10 | Gilead Sciences, Inc. | Crystalline forms of darunavir |
JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 |
TW201835068A (zh) | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
TW202402300A (zh) | 2017-01-31 | 2024-01-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ, インコーポレイテッド | 治療用複素環式化合物 |
JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
US20190151307A1 (en) | 2017-10-24 | 2019-05-23 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11253524B2 (en) | 2018-01-19 | 2022-02-22 | Gilead Sciences, Inc. | Metabolites of bictegravir |
CA3089590C (en) | 2018-02-15 | 2022-12-06 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
JP7296398B2 (ja) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチド |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
CA3102859A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
US20210393631A1 (en) | 2018-09-19 | 2021-12-23 | Gilead Sciences, Inc. | Integrase inhibitors for the prevention of hiv |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
JP2023502530A (ja) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv予防のためのカプシド阻害剤 |
CA3165735A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3166480A1 (en) | 2020-02-24 | 2021-09-02 | Lan Jiang | Tetracyclic compounds for treating hiv infection |
CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
WO2021262990A1 (en) | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
US20220119426A1 (en) | 2020-08-07 | 2022-04-21 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
JP2023543059A (ja) | 2020-09-30 | 2023-10-12 | ギリアード サイエンシーズ, インコーポレイテッド | 架橋三環式カルバモイルピリドン化合物及びその使用 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
PE20231297A1 (es) | 2021-01-19 | 2023-08-22 | Gilead Sciences Inc | Compuestos de piridotriazina sustituidos y usos de estos |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
US20230212148A1 (en) | 2021-12-03 | 2023-07-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895028A (en) * | 1972-09-12 | 1975-07-15 | Tokyo Tanabe Co | Alpha-(2-phenylbenzothiazol-5-yl)propionic acid |
JPS4994667A (es) * | 1973-01-23 | 1974-09-09 | ||
FR2453163A1 (fr) * | 1979-04-03 | 1980-10-31 | Rolland Sa A | Derives de benzothiazole, leur procede de preparation et leurs applications en therapeutique |
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
GB8403739D0 (en) | 1984-02-13 | 1984-03-14 | Roussel Lab Ltd | Chemical compounds |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
JPH03287558A (ja) | 1990-04-05 | 1991-12-18 | Teijin Ltd | 酵素阻害剤 |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
US5733906A (en) | 1993-10-12 | 1998-03-31 | Eli Lilly And Company | Inhibitors of HIV Protease useful for the treatment of Aids |
MX9308016A (es) | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
AU6497694A (en) | 1993-04-02 | 1994-10-24 | Ribogene, Inc. | Method for selective inactivation of viral replication |
JP3287558B2 (ja) | 1993-07-27 | 2002-06-04 | 株式会社半導体エネルギー研究所 | 半導体装置の作製方法 |
US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
DE4428932A1 (de) | 1994-08-16 | 1996-02-22 | Hoechst Ag | Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
JP2002511441A (ja) | 1998-04-09 | 2002-04-16 | メルク エンド カムパニー インコーポレーテッド | 過ヨウ素酸を用いる酸化方法 |
WO2000063152A1 (en) | 1999-02-22 | 2000-10-26 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Acetylated and related analogues of chicoric acid as hiv integrase inhibitors |
US20020052323A1 (en) | 2000-08-30 | 2002-05-02 | Jinhai Wang | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents |
AU2002225731B2 (en) | 2000-11-21 | 2005-04-14 | Sunesis Pharmaceuticals, Inc. | An extended tethering approach for rapid identification of ligands |
FR2819507B1 (fr) | 2001-01-17 | 2007-09-28 | Inst Rech Developpement Ird | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
FR2839646B1 (fr) | 2002-05-17 | 2008-04-11 | Bioalliance Pharma | Utilisation de derives de quinoleine a effet anti-integrase et ses applications |
BR0305717A (pt) * | 2002-08-02 | 2004-09-28 | Tibotec Pharm Ltd | Inibidores da protease do hiv 2-amino-benzotiazol sulfonamida de amplo espectro |
JP4879484B2 (ja) * | 2002-08-02 | 2012-02-22 | テイボテク・フアーマシユーチカルズ・リミテツド | 広スペクトルの2−アミノ−ベンゾチアゾールスルホンアミドhivプロテアーゼ阻害剤 |
ATE404537T1 (de) | 2002-08-13 | 2008-08-15 | Shionogi & Co | Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung |
US7514233B2 (en) | 2002-09-26 | 2009-04-07 | K.U. Leuven Research & Development | Integrase cofactor |
CZ2004764A3 (cs) | 2002-11-20 | 2005-02-16 | Japan Tobacco Inc | 4-Oxochinolinová sloučenina a její použití jako inhibitoru HIV-integrázy |
UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
EP1753740A2 (en) | 2004-05-21 | 2007-02-21 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
US7087610B2 (en) * | 2004-06-03 | 2006-08-08 | Bristol-Myers Squibb Company | Benzothiazole antiviral agents |
CN101006042A (zh) | 2004-06-22 | 2007-07-25 | 史密丝克莱恩比彻姆公司 | 化合物 |
TWI306401B (en) | 2004-08-13 | 2009-02-21 | Nat Health Research Institutes | Benzothiazolium compounds |
US20060094755A1 (en) | 2004-10-28 | 2006-05-04 | Bioflexis, Llc | Novel quinoline-based metal chelators as antiviral agents |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
EP2032578A2 (en) | 2006-05-30 | 2009-03-11 | Pfizer Products Incorporated | Triazolopyridazine derivatives |
JO2841B1 (en) * | 2006-06-23 | 2014-09-15 | تيبوتيك فارماسيوتيكالز ليمتد | 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV) |
US8435774B2 (en) | 2006-06-28 | 2013-05-07 | Qiagen Gmbh | Enhancing reactivation of thermostable reversibly inactivated enzymes |
WO2008053478A2 (en) | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
CA2671478C (en) | 2006-12-13 | 2015-02-17 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
EP2220095B1 (en) * | 2007-11-15 | 2013-01-02 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
JP5269086B2 (ja) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
EP2220084B1 (en) | 2007-11-16 | 2014-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
UA100250C2 (uk) | 2007-11-16 | 2012-12-10 | Гілеад Сайнсіз, Інк. | Інгібітори реплікації вірусу імунодефіциту людини |
GB0801940D0 (en) | 2008-02-01 | 2008-03-12 | Univ Leuven Kath | Inhibitors of lentiviral replication |
WO2009099982A1 (en) | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
JP5743897B2 (ja) | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 化合物 |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
AU2010266570A1 (en) | 2009-06-30 | 2012-01-19 | Siga Technologies, Inc. | Treatment and prevention of Dengue virus infections |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
SG10201408512RA (en) | 2009-12-23 | 2015-02-27 | Univ Leuven Kath | Novel antiviral compounds |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
CN103153994B (zh) | 2010-05-24 | 2016-02-10 | 罗切斯特大学 | 双环杂芳基激酶抑制剂及使用方法 |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
CA2802308C (en) | 2010-07-02 | 2018-08-28 | Lianhong Xu | Napht-2-ylacetic acid derivatives to treat aids |
US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
BR112013011991A2 (pt) | 2010-11-15 | 2016-08-30 | Viiv Healthcare Uk Ltd | composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit. |
JP2013542243A (ja) | 2010-11-15 | 2013-11-21 | カトリーケ ウニヴェルシテイト ルーヴェン | 新規な抗ウイルス性化合物 |
TWI538905B (zh) | 2010-12-22 | 2016-06-21 | H 朗德貝克公司 | 雙環[3.2.1]辛基醯胺衍生物及其用途 |
WO2012102985A1 (en) | 2011-01-24 | 2012-08-02 | Glaxosmithkline Llc | Isoquinoline compounds and methods for treating hiv |
TW201302761A (zh) | 2011-04-04 | 2013-01-16 | Gilead Sciences Inc | Hiv抑制劑之固態形式 |
JP2014511859A (ja) | 2011-04-04 | 2014-05-19 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤の調製のためのプロセス |
EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2511273B8 (en) | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
AP3491A (en) | 2011-04-21 | 2015-12-31 | Bayer Ip Gmbh | Triazolopyridines |
MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
TWI606049B (zh) | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
US9499535B2 (en) | 2011-04-21 | 2016-11-22 | Origenis Gmbh | Kinase inhibitors |
WO2013002357A1 (ja) | 2011-06-30 | 2013-01-03 | 塩野義製薬株式会社 | Hiv複製阻害剤 |
US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2013043553A1 (en) | 2011-09-22 | 2013-03-28 | Glaxosmithkline Llc | Pyrrolopyridinone compounds and methods for treating hiv |
WO2013058448A1 (ko) | 2011-10-20 | 2013-04-25 | 한국해양연구원 | 내분비계 장애물질 노출에 대응하는 바다송사리 유전자 및 이를 이용한 수생태계 환경오염 진단 방법 |
US9199959B2 (en) | 2011-10-25 | 2015-12-01 | Shionogi & Co., Ltd. | HIV replication inhibitor |
US8332160B1 (en) * | 2011-11-17 | 2012-12-11 | Amyris Biotechnologies, Inc. | Systems and methods for engineering nucleic acid constructs using scoring techniques |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
KR102204989B1 (ko) | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2013157622A1 (ja) | 2012-04-19 | 2013-10-24 | 塩野義製薬株式会社 | Hiv複製阻害剤 |
MD20140063A2 (ro) | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV |
EP2877468B1 (en) | 2012-07-12 | 2017-08-23 | ViiV Healthcare UK Limited | Compounds and methods for treating hiv |
US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US20140094609A1 (en) | 2012-10-03 | 2014-04-03 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
-
2012
- 2012-04-20 MX MX2013012266A patent/MX2013012266A/es unknown
- 2012-04-20 EP EP16196723.7A patent/EP3181555B1/en active Active
- 2012-04-20 PE PE2013002347A patent/PE20141066A1/es not_active Application Discontinuation
- 2012-04-20 EP EP12719182.3A patent/EP2699558B1/en active Active
- 2012-04-20 KR KR1020137030857A patent/KR20140027295A/ko not_active Application Discontinuation
- 2012-04-20 SG SG2013077110A patent/SG194512A1/en unknown
- 2012-04-20 UA UAA201312204A patent/UA111841C2/uk unknown
- 2012-04-20 AP AP2013007249A patent/AP2013007249A0/xx unknown
- 2012-04-20 EA EA201391395A patent/EA024952B1/ru unknown
- 2012-04-20 CN CN201610177497.3A patent/CN105712948A/zh active Pending
- 2012-04-20 ES ES16196723T patent/ES2707997T3/es active Active
- 2012-04-20 PT PT127191823T patent/PT2699558T/pt unknown
- 2012-04-20 JP JP2014506609A patent/JP5918848B2/ja active Active
- 2012-04-20 CN CN201280029211.7A patent/CN103797001B/zh active Active
- 2012-04-20 AU AU2012245187A patent/AU2012245187B2/en active Active
- 2012-04-20 ES ES12719182.3T patent/ES2615734T3/es active Active
- 2012-04-20 AP AP2015008931A patent/AP2015008931A0/xx unknown
- 2012-04-20 CA CA2833377A patent/CA2833377C/en active Active
- 2012-04-20 WO PCT/US2012/034593 patent/WO2012145728A1/en active Application Filing
- 2012-04-20 US US14/112,473 patent/US9006229B2/en active Active
- 2012-04-20 BR BR112013027096A patent/BR112013027096A2/pt not_active IP Right Cessation
-
2013
- 2013-10-17 CL CL2013003019A patent/CL2013003019A1/es unknown
- 2013-10-17 IL IL228925A patent/IL228925A0/en unknown
- 2013-10-31 CR CR20130560A patent/CR20130560A/es unknown
- 2013-11-14 CO CO13268123A patent/CO6801774A2/es unknown
- 2013-11-14 EC ECSP13013021 patent/ECSP13013021A/es unknown
- 2013-11-14 MA MA36432A patent/MA35804B1/fr unknown
-
2015
- 2015-02-26 US US14/632,771 patent/US9464096B2/en active Active
- 2015-09-11 PH PH12015502056A patent/PH12015502056A1/en unknown
-
2016
- 2016-01-27 JP JP2016012970A patent/JP2016065110A/ja active Pending
- 2016-09-06 US US15/257,482 patent/US9879023B2/en active Active
- 2016-09-29 AU AU2016234985A patent/AU2016234985C1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
ECSP13012418A (es) | Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih | |
DOP2019000201A (es) | Compuestos inhibidores del vih | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
EA202190619A1 (ru) | Противовирусные соединения | |
CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
EA201391127A1 (ru) | C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
MX347596B (es) | Derivados de purina para el tratamiento de infecciones viricas. | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
AR090241A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201492016A1 (ru) | C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
CY1115983T1 (el) | Συνθεση toy aliskiren | |
BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? |